Cargando…
Factors Attenuating Zinc Deficiency Improvement in Direct-Acting Antiviral Agent-Treated Chronic Hepatitis C Virus Infection
Zinc deficiency is frequently observed in chronic liver diseases. However, no studies have focused on the zinc status in chronic hepatitis C (HCV)-infected patients receiving direct-acting antiviral agents (DAAs). In this retrospective study, we assessed the serum zinc status in DAA-treated HCV pati...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6266757/ https://www.ncbi.nlm.nih.gov/pubmed/30400133 http://dx.doi.org/10.3390/nu10111620 |
_version_ | 1783375912067137536 |
---|---|
author | Ko, Yi-Ling Morihara, Daisuke Shibata, Kumiko Yamauchi, Ryo Fukuda, Hiromi Kunimoto, Hideo Takata, Kazuhide Tanaka, Takashi Inomata, Shinjiro Yokoyama, Keiji Takeyama, Yasuaki Shakado, Satoshi Sakisaka, Shotaro |
author_facet | Ko, Yi-Ling Morihara, Daisuke Shibata, Kumiko Yamauchi, Ryo Fukuda, Hiromi Kunimoto, Hideo Takata, Kazuhide Tanaka, Takashi Inomata, Shinjiro Yokoyama, Keiji Takeyama, Yasuaki Shakado, Satoshi Sakisaka, Shotaro |
author_sort | Ko, Yi-Ling |
collection | PubMed |
description | Zinc deficiency is frequently observed in chronic liver diseases. However, no studies have focused on the zinc status in chronic hepatitis C (HCV)-infected patients receiving direct-acting antiviral agents (DAAs). In this retrospective study, we assessed the serum zinc status in DAA-treated HCV patients with sustained virologic response for over two years (Zn-2y). Ninety-five patients were enrolled, whose baseline characteristics and blood parameters at DAA therapy initiation were collected. Baseline Zn < 65 µg/dL (odds ratio (OR) = 10.56, p < 0.001) and baseline uric acid (UA) > 5.5 mg/dL (OR = 9.99, p = 0.001) were independent risk factors for Zn-2y deficiency. A decision-tree algorithm classified low-baseline Zn and high-baseline UA as the first two variables, suggesting that baseline hypozincemia and hyperuricemia are prognosticators for long-term zinc deficiency. Baseline Zn was negatively correlated with the Fibrosis-4 (FIB-4) index, while baseline UA was significantly higher in habitual alcohol drinkers. In conclusion, serum zinc levels should be closely monitored, considering that zinc status improvement is related to liver fibrosis regression. Hyperuricemia indicates risks of developing metabolic disorders and subsequent zinc deficiency, for which an adjustment of personal lifestyle or dietary habits should be recommended clinically. |
format | Online Article Text |
id | pubmed-6266757 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-62667572018-12-06 Factors Attenuating Zinc Deficiency Improvement in Direct-Acting Antiviral Agent-Treated Chronic Hepatitis C Virus Infection Ko, Yi-Ling Morihara, Daisuke Shibata, Kumiko Yamauchi, Ryo Fukuda, Hiromi Kunimoto, Hideo Takata, Kazuhide Tanaka, Takashi Inomata, Shinjiro Yokoyama, Keiji Takeyama, Yasuaki Shakado, Satoshi Sakisaka, Shotaro Nutrients Article Zinc deficiency is frequently observed in chronic liver diseases. However, no studies have focused on the zinc status in chronic hepatitis C (HCV)-infected patients receiving direct-acting antiviral agents (DAAs). In this retrospective study, we assessed the serum zinc status in DAA-treated HCV patients with sustained virologic response for over two years (Zn-2y). Ninety-five patients were enrolled, whose baseline characteristics and blood parameters at DAA therapy initiation were collected. Baseline Zn < 65 µg/dL (odds ratio (OR) = 10.56, p < 0.001) and baseline uric acid (UA) > 5.5 mg/dL (OR = 9.99, p = 0.001) were independent risk factors for Zn-2y deficiency. A decision-tree algorithm classified low-baseline Zn and high-baseline UA as the first two variables, suggesting that baseline hypozincemia and hyperuricemia are prognosticators for long-term zinc deficiency. Baseline Zn was negatively correlated with the Fibrosis-4 (FIB-4) index, while baseline UA was significantly higher in habitual alcohol drinkers. In conclusion, serum zinc levels should be closely monitored, considering that zinc status improvement is related to liver fibrosis regression. Hyperuricemia indicates risks of developing metabolic disorders and subsequent zinc deficiency, for which an adjustment of personal lifestyle or dietary habits should be recommended clinically. MDPI 2018-11-02 /pmc/articles/PMC6266757/ /pubmed/30400133 http://dx.doi.org/10.3390/nu10111620 Text en © 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Ko, Yi-Ling Morihara, Daisuke Shibata, Kumiko Yamauchi, Ryo Fukuda, Hiromi Kunimoto, Hideo Takata, Kazuhide Tanaka, Takashi Inomata, Shinjiro Yokoyama, Keiji Takeyama, Yasuaki Shakado, Satoshi Sakisaka, Shotaro Factors Attenuating Zinc Deficiency Improvement in Direct-Acting Antiviral Agent-Treated Chronic Hepatitis C Virus Infection |
title | Factors Attenuating Zinc Deficiency Improvement in Direct-Acting Antiviral Agent-Treated Chronic Hepatitis C Virus Infection |
title_full | Factors Attenuating Zinc Deficiency Improvement in Direct-Acting Antiviral Agent-Treated Chronic Hepatitis C Virus Infection |
title_fullStr | Factors Attenuating Zinc Deficiency Improvement in Direct-Acting Antiviral Agent-Treated Chronic Hepatitis C Virus Infection |
title_full_unstemmed | Factors Attenuating Zinc Deficiency Improvement in Direct-Acting Antiviral Agent-Treated Chronic Hepatitis C Virus Infection |
title_short | Factors Attenuating Zinc Deficiency Improvement in Direct-Acting Antiviral Agent-Treated Chronic Hepatitis C Virus Infection |
title_sort | factors attenuating zinc deficiency improvement in direct-acting antiviral agent-treated chronic hepatitis c virus infection |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6266757/ https://www.ncbi.nlm.nih.gov/pubmed/30400133 http://dx.doi.org/10.3390/nu10111620 |
work_keys_str_mv | AT koyiling factorsattenuatingzincdeficiencyimprovementindirectactingantiviralagenttreatedchronichepatitiscvirusinfection AT moriharadaisuke factorsattenuatingzincdeficiencyimprovementindirectactingantiviralagenttreatedchronichepatitiscvirusinfection AT shibatakumiko factorsattenuatingzincdeficiencyimprovementindirectactingantiviralagenttreatedchronichepatitiscvirusinfection AT yamauchiryo factorsattenuatingzincdeficiencyimprovementindirectactingantiviralagenttreatedchronichepatitiscvirusinfection AT fukudahiromi factorsattenuatingzincdeficiencyimprovementindirectactingantiviralagenttreatedchronichepatitiscvirusinfection AT kunimotohideo factorsattenuatingzincdeficiencyimprovementindirectactingantiviralagenttreatedchronichepatitiscvirusinfection AT takatakazuhide factorsattenuatingzincdeficiencyimprovementindirectactingantiviralagenttreatedchronichepatitiscvirusinfection AT tanakatakashi factorsattenuatingzincdeficiencyimprovementindirectactingantiviralagenttreatedchronichepatitiscvirusinfection AT inomatashinjiro factorsattenuatingzincdeficiencyimprovementindirectactingantiviralagenttreatedchronichepatitiscvirusinfection AT yokoyamakeiji factorsattenuatingzincdeficiencyimprovementindirectactingantiviralagenttreatedchronichepatitiscvirusinfection AT takeyamayasuaki factorsattenuatingzincdeficiencyimprovementindirectactingantiviralagenttreatedchronichepatitiscvirusinfection AT shakadosatoshi factorsattenuatingzincdeficiencyimprovementindirectactingantiviralagenttreatedchronichepatitiscvirusinfection AT sakisakashotaro factorsattenuatingzincdeficiencyimprovementindirectactingantiviralagenttreatedchronichepatitiscvirusinfection |